North China Pharmaceutical Co., Ltd. (600812)(製薬・医療分野):企業M&A動向

GlobalDataが出版した調査資料(GDPH207627D)
◆英語タイトル:North China Pharmaceutical Co., Ltd. (600812) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:GDPH207627D
◆発行会社(調査会社):GlobalData
◆発行日:2015年3月27日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:中国
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD500 ⇒換算¥55,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD750 ⇒換算¥82,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary

North China Pharmaceutical Co., Ltd. (NCPC) is a pharmaceutical company. The company develops, produces and sells novel drugs and pharmaceutical related products. Its products include benproperine phosphate, vitamin EC particles, bismuth potassium citrate, compound paracetamol, pediatric dimensional calcium portugal, vitamin B1 particles benorilate, children paracetamol huang min particles, relying erythromycin particles, erythromycin particles, pediatric dual sulfur particles, and pediatric sulfamethoxazole particles. NCPC offers products in the dosage forms of granules, capsules, and tablets. The company markets products across the US, the Democratic Republic of Congo, India, Dubai, and Europe. NCPC is headquartered in Shijiazhuang, Hebei, China.

North China Pharmaceutical Co., Ltd. (600812) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
North China Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
North China Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 6
North China Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 7
North China Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8
North China Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 9
North China Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Royal DSM Terminates Joint Ventures With North China Pharma 10
Equity Offering 11
North China Pharma Receives Approval From China Securities Regulatory Commission For Private Placement Of Shares For US$183.4 Million 11
North China Pharma Completes Private Placement Of Shares For US$471 Million 12
North China Pharma Announces Private Placement Of Common Stock For US$466 Million 13
Debt Offering 15
North China Pharma Announces Public Offering Of Notes For US$73 Million 15
Acquisition 16
North China Pharma To Acquire Remaining 50% Stake In Pharmaceutical Company For US$14.2 Million 16
Jointown Pharma To Acquire 49% Stake In NCPC International For US$9.7 Million 17
North China Pharma To Acquire A Medicine Company For US$151.15 Million 18
Royal DSM Terminates Acquisition Of 10% stake In North China Pharma 19
North China Pharmaceutical Co., Ltd. – Key Competitors 20
Locations And Subsidiaries 21
Head Office 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
North China Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Key Facts, 2013 1
North China Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
North China Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 6
North China Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 7
North China Pharmaceutical Co., Ltd., Deals By Therapy Area, 2009 to YTD 2015 8
North China Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 9
Royal DSM Terminates Joint Ventures With North China Pharma 10
North China Pharma Receives Approval From China Securities Regulatory Commission For Private Placement Of Shares For US$183.4 Million 11
North China Pharma Completes Private Placement Of Shares For US$471 Million 12
North China Pharma Announces Private Placement Of Common Stock For US$466 Million 13
North China Pharma Announces Public Offering Of Notes For US$73 Million 15
North China Pharma To Acquire Remaining 50% Stake In Pharmaceutical Company For US$14.2 Million 16
Jointown Pharma To Acquire 49% Stake In NCPC International For US$9.7 Million 17
North China Pharma To Acquire A Medicine Company For US$151.15 Million 18
Royal DSM Terminates Acquisition Of 10% stake In North China Pharma 19
North China Pharmaceutical Co., Ltd., Key Competitors 20

List of Figures
North China Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 1
North China Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 1
North China Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 1
North China Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 1
North China Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
North China Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 6
North China Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 7
North China Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8

★調査レポート[North China Pharmaceutical Co., Ltd. (600812)(製薬・医療分野):企業M&A動向] (コード:GDPH207627D)販売に関する免責事項を必ずご確認ください。
★調査レポート[North China Pharmaceutical Co., Ltd. (600812)(製薬・医療分野):企業M&A動向]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆